Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A novel class of non-nucleoside HCV NS5B polymerase inhibitors has been identified from screening. A co-crystal structure revealed an allosteric binding site in the protein that required a unique conformational change to accommodate inhibitor binding. Herein we report the structure-activity relationships (SARs) of this novel class of dihydropyrone-containing compounds that show potent inhibitory activities against the HCV RNA polymerase in biochemical assays.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2006.06.065 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells.
PLoS Pathog
September 2025
Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Hepatitis C virus (HCV) exhibits a narrow species tropism, causing robust infections only in humans and experimentally inoculated chimpanzees. While many host factors and restriction factors are known, many more likely remain unknown, which has limited the development of mouse or other small animal models for HCV. One putative restriction factor, the black flying fox orthologue of receptor transporter protein 4 (RTP4), was previously shown to potently inhibit viral genome replication of several ER-replicating RNA viruses.
View Article and Find Full Text PDFHepatitis C (HCV) infection is a major global health challenge, with particularly high prevalence among people who inject drugs (PWID) in the Eastern European and Central Asian region (EECA). While the country of Georgia has made major progress in reducing overall HCV prevalence, less is known about HCV reinfection rates and risk factors for reinfection among PWID. In this study, we aimed to: (1) estimate HCV reinfection rates and (2) identify risk factors associated with HCV reinfection among PWID.
View Article and Find Full Text PDFHepatitis C virus testing in infants, a move to early screening by HCV RNA at 2 months of age.
Paediatr Child Health
August 2025
Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, Ontario, Canada.
In the last decade, hepatitis C virus (HCV) has become a curable chronic viral infection, with excellent treatment and streamlined diagnostic testing. Canada and many other countries have adopted national elimination targets; however, reaching these goals will require changes in the way care is provided. Standard of care HCV treatment is all-oral daily medication for 8 or 12 weeks and all provinces in Canada have mechanisms for public coverage.
View Article and Find Full Text PDFManagement of Pediatric Chronic Hepatitis C with Crushed or Split Glecaprevir/Pibrentasvir: A Case Series From East Jeddah Hospital, Saudi Arabia.
Int Med Case Rep J
September 2025
Drug Information Center, Department of Pharmacy, East Jeddah Hospital, Ministry of Health, Jeddah, 23816, Saudi Arabia.
Purpose: Glecaprevir/Pibrentasvir (GLE/PIB) is approved for chronic hepatitis C treatment in both adults and pediatric patients, no data regarding crushing this drug in pediatric populations. This case series evaluate the efficacy and safety of crushed or split GLE/PIB tablets in two pediatric patients at East Jeddah Hospital, Saudi Arabia.
Patients And Methods: Two treatment-naïve pediatric patients with normal liver function received weight-based GLE/PIB for eight weeks.
Early Read-Time Performance of the OraQuick HCV Rapid Antibody Assay for the Exclusion of HCV Viremia.
J Viral Hepat
October 2025
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Rapid point-of-care tests for hepatitis C virus (HCV) provide results in 20 min and allow linkage to care, particularly for difficult-to-reach populations. Prior work suggested an early reading time of the OraQuick (OQ) rapid HCV antibody lateral flow immunoassay identified people with HCV viremia; however, these observations were not externally validated. We conducted a prospective cohort study at Penn Presbyterian Medical Center from June 2021 to August 2023 to evaluate the performance of OQ early reading times for HCV viremia among participants with reactive HCV antibody.
View Article and Find Full Text PDF